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Saving lives through improved use of ACTs
The new modelling work by Tran Dang Nguyen and 
colleagues in The Lancet Global Health,1 which focuses 
on optimum distribution strategies of artemisinin 
combination therapies (ACTs) for treatment of malaria, 
comes at a crucial juncture in the public health battle to 
contain drug resistance. At a time that many countries 
are heeding calls to develop aggressive national plans 
to eliminate malaria and are reporting encouraging 
news of declining morbidity and mortality, worrisome 
evidence in the Greater Mekong subregion of southeast 
Asia conﬁ rms that resistance to artemisinin and to 
non-artemisinin partner drugs used in ACTs remains a 
threat.2 Safeguarding the eﬀ ectiveness of ACTs should 
remain a paramount concern of the malaria community, 
and choosing optimum strategies for distribution of 
the various ACT options available to countries is a key 
component of this challenge.
Availability of several ACTs has fuelled years of debate 
and modelling eﬀ orts to understand how this range 
of options can best be used to safeguard this class of 
treatments. Boni and colleagues3 ﬁ rst suggested the 
superior performance of concomitant use of multiple 
ﬁ rst-line therapies (MFT) over sequential application 
of single ﬁ rst-line therapies with an evolutionary–
epidemiological modelling framework. By use of 
hybrid modelling approaches, Smith and colleagues4 
also showed that, compared with sequential use of 
single ﬁ rst-line antimalarial drugs, MFT strategies were 
more eﬀ ective in reducing drug pressure and delaying 
emergence and spread of resistance. However, with 
a population genetics model, Antao and Hastings5 
suggested that the advantage of MFT over sequential 
application was not as clearly advantageous as other 
models had shown, owing to linkage disequilibrium that 
could yield multidrug resistance earlier than sequential 
application. These discrepant outputs led the WHO Drug 
Resistance and Containment Technical Expert Group in 
2013 to declare that evidence for the beneﬁ ts of MFT 
was inconclusive but that the concept was crucially 
important and warranted further modelling.6
This new work by Nguyen and colleagues is a 
signiﬁ cant improvement over past eﬀ orts at modelling 
the eﬀ ect of MFT. The model relies on individual-based 
microsimulation of regional malaria transmission, 
taking into consideration individual-level host detail, 
age-speciﬁ c eﬀ ects, explicit tracking of within-host 
parasite density, and drug-speciﬁ c pharmacodynamics. 
Importantly, outputs from this model provide 
powerful evidence that, compared with drug cycling 
strategies or sequential deployment of diﬀ erent 
ACTs, MFT strategies are signiﬁ cantly better at 
delaying emergence of resistance to both artemisinin 
derivatives and their partner drugs.
The implications of this modelling study invite 
reﬂ ection about the crucial role that ACTs have had 
for the past 15 years. Although artemisinins used in 
monotherapy are mostly eﬀ ective at clearing malaria 
parasites, the objective of recommending their 
combination with other antimalarial drugs was to 
protect the artemisinin component from resistance, 
as long as the partner drug itself was eﬃ  cacious and 
also partly protected by the artemisinin derivative.7 
Fortunately, development of ﬁ xed-dose combinations 
of ACTs, advocacy to discourage monotherapy, reduced 
prices, and improved availability have all contributed 
to widespread use of these life-saving medicines. 
Together with vector control eﬀ orts, use of ACTs has 
contributed to a substantial reduction in the global 
malaria mortality rate by 47% (54% in Africa) between 
2000 and 2013.8 Four highly eﬀ ective ﬁ xed-dose ACTs 
are recommended by WHO at present for treatment 
of uncomplicated malaria, and they have a crucial role 
in malaria elimination eﬀ orts. Thus, drug resistance 
spreading to Africa would have disastrous eﬀ ects on 
millions of patients—and a crippling eﬀ ect on the 
malaria elimination agenda.
Building on the authors’ validation of their model 
against a wide range of ﬁ eld and clinical datasets, 
further scrutiny of this model by other disease modellers 
would be welcome, especially by those experienced in 
modelling drug eﬀ ectiveness in the event of resistance. 
If the debate about MFT ﬁ nally moves beyond the 
purview of modellers into the hands of policy makers 
and implementing programmes, future research should 
focus on operational considerations linked to MFT, 
including new commodity forecasting needs, supply 
chain capability, and training of health workers in use 
of several alternative therapies. Finally, operational 
research should assess the feasibility of diﬀ erent options 
for randomisation of ACT use in patient populations.
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